This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.
Invokana® (canagliflozin) is a drug prescribed to treat Type 2 diabetes. It belongs to a new class of drugs referred to as “Sodium Glucose co-transporter 2 (SGLT2) inhibitors.” Approved for sale by the FDA in 2013, Invokana was the first of this new class to be sold in the United States. Invokana® and its related drugs, Invokamet® and Invokamet® XR are manufactured and sold by Johnson & Johnson and its subsidiary Janssen Pharmaceuticals. Other SGLT2 inhibitors - Farxiga® and Xigduo® XR (Astra Zeneca) and Jardiance® and Glyxambi® (Boehringer Ingelheim & Eli Lilly) – were subsequently approved for sale in the U.S. Each of these drugs comes in two forms: one as the sole drug and the other as a combination drug that includes the branded drug.
Invokamet® and Invokamet® XR are versions of Invokana® that are formulated by adding metformin, the most commonly prescribed diabetes drug for people suffering from Type 2 diabetes. Invokamet® XR is an extended release version of Invokamet®. While Invokamet® is taken twice daily and fast-acting, Invokamet® XR is taken once daily and is slower acting.
Jardiance® and Farxiga® are SGLT2 inhibitors that are also prescribed to Type 2 diabetes patients to help improve glycemic control. Farxiga® (dapagliflozin), and its metformin-combination formulation Xigduo® XR, are manufactured and sold by AstraZeneca Pharmaceuticals and Bristol Meyers Squibb. Jardiance® (empagliflozin), and its metformin-combination formulation Glyxambi®, are manufactured and sold by Boehringer Ingelheim Pharmaceuticals and Eli Lilly.
SGLT2 Inhibitors are designed to treat diabetes in a novel fashion: by targeting the kidneys and promoting the excretion of glucose through urine. This mechanism of action works independently of the body’s supply of insulin. By blocking (inhibiting) a key transport protein that is active in renal filtration, SGLT2 Inhibitors cause glucose to be excreted in the urine rather than allowing it to re-circulate throughout the body.
There are reportedly over 21 million U.S. adults taking some form of glucose-lowering medications with approximately 35% of them age 45 and older. Of the 21 million, over 90% suffer from Type 2 diabetes. These numbers are expected to increase as the U.S. population ages and the prevalence of obesity increases.
This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.